

Supplemental Table for:
 Efficacy and Safety of Everolimus in Extra-Pancreatic NET: A Comprehensive Review of Literature
 Pasqualino Malandrino et al.

Table S1. Treatments before everolimus in NET patients.

Surgery	Chemotherapy	SSA	Interferon	TKI	LRT	PRRT	Radiotherapy
NA	8 (36%)	18 (82%)	4 (18%)	13 (59%)	5 (23%)	0	0
NA	NS	NS	0	NS	NS	0	0
NA	25 (42%)	38 (63%)	9 (15%)	6 (10%)	5 (8%)	0	0
NA	25 (73%)	0	0	0	0	0	9 (26%)
27 (68%)	9 (22%)	0	0	1 (2%)	0	0	6 (15%)
25 (50%)	0	0	0	0	0	0	0
NA	75 (35%)	173 (84%)	NA	0	NA	0	0
NA	7 (37%)	13 (68%)	0	0	0	0	0
NA	13 (39%)	22 (67%)	0	5 (15%)	0	0	0
7 (50%)	2 (14%)	1 (7%)	2 (14%)	1 (7%)	0	1 (7%)	3 (21%)
11 (46%)	8 (33%)	14 (58%)	1 (4%)	0	0	24 (100%)	0
NS	84 (50%)	157 (93%)	18 (11%)	0	NA	85 (50%)	0
1 (100%)	0	1 (100%)	1 (100%)	0	1 (100%)	0	0
1 (100%)	1 (100%)	1 (100%)	0	0	0	0	1
1 (100%)	1 (100%)	1 (100%)	1 (100%)	0	0	0	0
2 (100%)	0	2 (100%)	0	0	0	1 (50%)	1 (50%)
1 (100%)	0	0	0	0	0	0	0
0	1 (100%)	1 (100%)	0	0	0	0	0
1 (100%)	0	1 (100%)	0	0	1 (100%)	1 (100%)	0
1 (100%)	0	1 (100%)	0	0	0	0	0
NA	NA	NA	NA	0	NA	0	0
1 (100%)	0	1 (100%)	0	0	1	0	0

Supplemental Table for:
Efficacy and Safety of Everolimus in Extra-Pancreatic NET: A Comprehensive Review of Literature
Pasqualino Malandrino et al.

NA: not available